TOP TEN perturbations for 39955_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39955_at
Selected probe(set): 1564443_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39955_at (1564443_at) across 6674 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):-1.6192493
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):-1.3199053
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

breast cancer study 42 (metastase; liver) / breast cancer study 42 (metastase; chest wall)

Relative Expression (log2-ratio):-1.2785215
Number of Samples:3 / 2
Experimental breast cancer study 42 (metastase; liver)
Metastatic tumor tissue obtained from the liver of patients with primary breast adenocarcinoma.
Control breast cancer study 42 (metastase; chest wall)
Metastatic tumor tissue obtained from the chest wall of patients with primary breast adenocarcinoma.

asthma study 22 (eosinophilic AIP) / asthma study 22 (neutrophilic AIP)

Relative Expression (log2-ratio):-1.2095261
Number of Samples:15 / 17
Experimental asthma study 22 (eosinophilic AIP)
Sputum samples from asthmatic patients with eosinophilic airway inflammatory phenotype (AIP).
Control asthma study 22 (neutrophilic AIP)
Sputum samples from asthmatic patients with neutrophilic airway inflammatory phenotype (AIP).

breast cancer study 42 (metastase; lymph node) / breast cancer study 42 (metastase; chest wall)

Relative Expression (log2-ratio):-1.1283503
Number of Samples:7 / 2
Experimental breast cancer study 42 (metastase; lymph node)
Metastatic tumor tissue obtained from the lymph node of patients with primary breast adenocarcinoma.
Control breast cancer study 42 (metastase; chest wall)
Metastatic tumor tissue obtained from the chest wall of patients with primary breast adenocarcinoma.

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):-1.1283054
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):-1.1154594
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

systemic lupus erythematosus study 13 (pioglitazone) / pioglitazone study 4 (1uM; 6h)

Relative Expression (log2-ratio):1.0962639
Number of Samples:4 / 5
Experimental systemic lupus erythematosus study 13 (pioglitazone)
Peripheral blood mononuclear cells (PBMCs) obtained from systemic lupus erythematosus (SLE) patients and cultured with pioglitazone. Lupus patients fulfilled American College of Rheumatology classification criteria for disease, and disease activity was quantified by SLEDAI. Patients were excluded if they showed symptoms of recent or active infection or were pregnant. None of the patients was taking Pioglitazone or other PPAR-γ agonists. ATC code:
Control pioglitazone study 4 (1uM; 6h)
Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects and cultured with pioglitazone. Freshly isolated PBMCs were cultured in RPMI/10% FBS in the presence of 1uM pioglitazone for 6 hours. ATC code:

asthma study 22 (neutrophilic AIP) / asthma study 22 (paucigranulocytic AIP)

Relative Expression (log2-ratio):1.0659504
Number of Samples:17 / 10
Experimental asthma study 22 (neutrophilic AIP)
Sputum samples from asthmatic patients with neutrophilic airway inflammatory phenotype (AIP).
Control asthma study 22 (paucigranulocytic AIP)
Sputum samples from asthmatic patients with paucigranulocytic airway inflammatory phenotype (AIP).

glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-1.04744
Number of Samples:3 / 3
Experimental glioma study 17 (glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.